WSAAI 60th Annual Scientific Session

Program Summary

 

Activity Information

Fairmont Orchid
One North Kaniku Drive
Kamuela, HI 96743

February 5 - 9, 2023

Please note: The WSAAI room block at the Fairmont Orchid is sold out.  Please contact email@wsaai.org to request overflow waitlist.

 

Target Audience

Practicing allergists and allied health care providers in the field of allergy and immunology.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the American College of Allergy, Asthma & Immunology (ACAAI) and the Western Society of Allergy, Asthma and Immunology (WSAAI).   The American College of Allergy, Asthma and Immunology (ACAAI) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Joint Providership

 

Jointly Provided by the American College of Allergy, Asthma & Immunology and the Western Association of Allergy, Asthma & Immunology.

Commercial Support

This activity is supported by commercial interests.

Learning Objectives

We are still collecting the objectives.  Please check back in the future for more details.

 

Disclosure Policy

As required by the Accreditation Council for Continuing Medical Education (ACCME) and in accordance with the American College of Allergy, Asthma and Immunology (ACAAI) policy, all educational planners, presenters, instructors, moderators, authors, reviewer, and other individuals in a position to control or influence the content of an activity must disclose ALL financial relationships with any ineligible company. The ACCME defines an “ineligible company” (formerly commercial interest) as a company whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. (Examples of ineligible companies include: Advertising, marketing, or communication firms whose clients are ineligible companies; bio-medical startups that have begun a governmental regulatory approval process; compounding pharmacies that manufacture proprietary compounds; device manufacturers or distributors; diagnostic labs that sell proprietary products; growers, distributors, manufacturers or sellers of medical foods and dietary supplements; manufacturers of health-related wearable products; pharmaceutical companies or distributors; pharmacy benefit managers; reagent manufacturers or sellers). For more information, visit www.accme.org.

Disclosure in no way implies that the information presented is biased or of lesser quality. It is incumbent upon course participants to be aware of these factors in interpreting the program contents and evaluating recommendations. Moreover, expressed views do not necessarily reflect the opinions of the ACAAI.

All identified relevant financial relationships have been mitigated.

Satellite Activities

Industry led lectures and exhibits will be conducted as optional learning opportunities in conjunction with this event. These optional activities are not certified for CME credit and are not planned or sanctioned by the American College of Allergy, Asthma and Immunology or WSAAI.

Planning Committee

The Board includes the following physicians: Steven Machtinger, M.D.; Matthew Bowdish, M.D.; Rene Anderson-Cowell, M.D.; David Elkayam, M.D.; Andrew White, M.D.; Neal Jain, M.D.; Marc Riedl, M.D., M.S.; Jinny Chang, M.D.

ADA Statement

in compliance with the Americans with Disabilities Act, WSAAI requests that any participant in need of accommodation send email to: karol@wsaai.org